

10/551819

JC20 Rec'd PCT/PTO 30 SEP 2009

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**ATTORNEY DOCKET NO. 065691-0408**

Applicant: Dominique BOUREL et al.

Title: THERAPEUTIC PRODUCTS WITH ENHANCED  
ABILITY TO IMMUNOMODULATE CELL FUNCTIONS

Appl. No.: Unassigned

Filing Date: 09/30/2005

Examiner: Unassigned

Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

Appl. No. Unassigned

Atty. Dkt. No. 065691-0408

(2) PRACTICE 30 SEP 2005  
**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the date of entry of the national stage as set forth in 37 CFR §1.491.


**RELEVANCE OF EACH DOCUMENT**

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding International application. A copy of the International Search Report setting forth the portion of each reference considered relevant by the examiner is attached. Copies of the documents are not being provided since copies should have been provided directly by WIPO under an exchange program between the PTO, the EPO and the JPO.

Applicants respectfully request that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

  
Stephen B. Maebius  
 Attorney for Applicant  
 Registration No. 35,264

September 30, 2005  
 Date

FOLEY & LARDNER LLP  
 Customer Number: 22428  
 Telephone: (202) 672-5569  
 Facsimile: (202) 672-5399

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></p> <p>(use as many sheets as necessary)</p>	<p><i>Complete if Known</i></p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td style="width: 50%;">Unassigned</td> </tr> <tr> <td>Filing Date</td> <td>09/30/2005</td> </tr> <tr> <td>First Named Inventor</td> <td>Dominique BOUREL et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>Unassigned</td> </tr> <tr> <td>Examiner Name</td> <td>Unassigned</td> </tr> <tr> <td>Attorney Docket Number</td> <td>065691-0408</td> </tr> </table>	Application Number	Unassigned	Filing Date	09/30/2005	First Named Inventor	Dominique BOUREL et al.	Group Art Unit	Unassigned	Examiner Name	Unassigned	Attorney Docket Number	065691-0408
Application Number	Unassigned												
Filing Date	09/30/2005												
First Named Inventor	Dominique BOUREL et al.												
Group Art Unit	Unassigned												
Examiner Name	Unassigned												
Attorney Docket Number	065691-0408												
Sheet	1	of	1										

## U.S. PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

## **NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
	A5	DAVIES et al., "Expression of GnTIII in A Recombinant Anti-CD20 CH0 Production Cell Line: Expression of Antibodies with altered Gycosforms Leads To An Increase In ADCC Through Higher Affinity of FcgammaRIII," Biotechnology and Bioengineering Combinatoial Chemistry, Vol. 74, No. 4, August 2001, pgs. 288-294.	
	A6	SHIELDS et al., "Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcgammaRIII and Antibody-Dependent Cellular Toxicity," Journal of Biological Chemistry, American Society of biological Chemists, Vol. 277, No. 30, July 26, 2002, pgs. 26733-26740.	
	A7	WRIGHT et al., "Effect of Glycosylation on Antibody Function: Implications For Genetic Engineering," Trends in Biotechnology, Elsevier Publications, Vol. 15, No. 1, 1997, pgs. 26-32.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO)

<sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.  
<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH 1471930.1